⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
URGN News
UroGen Pharma Ltd. Ordinary Shares
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
globenewswire.com
URGN
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
globenewswire.com
URGN
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
globenewswire.com
URGN
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
globenewswire.com
URGN
Bladder Cancer Patients Report Delayed Diagnosis and Gaps in Support
globenewswire.com
JNJ
FER
URGN
Form 8-K
sec.gov
URGN
Form 8-K
sec.gov
URGN
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
URGN
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
globenewswire.com
URGN
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
globenewswire.com
URGN